AstraZeneca Covid-19 vaccine

How AstraZeneca Covid vaccine ChAdOx1 nCoV-19 works

AstraZeneca with the University of Oxford is working on a COVID-19 vaccine- ChAdOx1 nCoV-19. The company’s COVID-19 vaccine is currently in phase-II/III clinical trials.

Yesterday they published the interim results for the ongoing phase-II trials. They claimed it found the vaccine is more effective and producing a strong immune response in older adults (more than 70 years old). This is an important factor as most of the vaccines don’t work well in old age people due to week immune systems. The study involved 560 adults, of which 240 were over the age of 70.

How AstraZeneca ChAdOx1 nCoV-19 works
  • The company extracted the DNA of Coronavirus and bioengineered it into a week virus, called adenovirus (a virus that causes the common cold). It is bioengineered in such a way that it can’t replicate in the human body.
  • The adenovirus then injected into a patient
  • It then enters the human body and binds itself to cells like Coronavirus.
  • This triggers the immune system to produce antibodies and T-cells to kill the infected cells
  • If the vaccinated person infected with Coronavirus in the future, then those antibodies and T-cells will be ready to attack Coronavirus and destroy it.
When will the AstraZeneca and University of Oxford’s vaccine will available

The company is planning to release the data for Phase-III in late December. According to the company CEO, the vaccine will be available in the next 3-4 months. In the first phase, essential workers and healthcare will be covered. The company is planning to manufacture 100 million doses by February 2021 end and 300-400 million doses by end of the first quarter. The UK government had signed an agreement with Indian pharma company Wockhardt to supply doses for its UK citizens.